Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$21.2M
Filings
66
Firms Hired
1
Active Period
2008–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2017 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to the Tax Cuts and Jobs Act H.R. 1 (115); issues relating to incentives for life sciences research; tax treatment of inverted companies; tax issues in mergers and acquisitions of US firms.
Client expense: $380,000 · Firm income: —
Matched citations: H.R. 1
Medicaid Generic Drug Price Fairness Act of 2014
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 5748
Protect Medical Innovation Act of 2015
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 160
To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 4641
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: H.R.471
Comprehensive Opioid Abuse Reduction Act of 2016
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 5046
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 6
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Client expense: $410,000 · Firm income: —
Matched citations: H.R. 9
Medicaid Generic Drug Price Fairness Act
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: S. 2948
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Client expense: $410,000 · Firm income: —
Matched citations: S. 1137
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: S. 483
Comprehensive Addiction and Recovery Act of 2016
2016 · fourth_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to FDA policy, including marketed new drugs without approved NDAs or ANDAs; issues relating to removal of FDA unapproved products from the market such as KCL and Adrenalin; H.R. 5046/S. 524 - Opioid abuse legislation.
Client expense: $410,000 · Firm income: —
Matched citations: S. 524
Medicaid Generic Drug Price Fairness Act of 2014
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 5748
Protect Medical Innovation Act of 2015
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 160
To provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 4641
Ensuring Patient Access and Effective Drug Enforcement Act of 2015
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: H.R.471
Comprehensive Opioid Abuse Reduction Act of 2016
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 5046
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 6
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Client expense: $290,000 · Firm income: —
Matched citations: H.R. 9
Medicaid Generic Drug Price Fairness Act
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: S. 2948
Oversight of implementation of the America Invents Act; issues relating to patent settlements; H.R. 9 - The Innovation Act; S. 1137 - Protecting American Talent and Entrepreneurship Act of 2015; issues relating to misuse of the inter pares review process.
Client expense: $290,000 · Firm income: —
Matched citations: S. 1137
Ensuring Patient Access and Effective Drug Enforcement Act of 2016
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: S. 483
Comprehensive Addiction and Recovery Act of 2016
2016 · third_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to Opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures bill (Senate companion which includes NIH and FDA issues); H.R.471, S. 483 - Ensuring Patient Access and Effective Drug Enforcement Act of 2015; S. 524 the Comprehensive Addiction and Recovery Act and related legislation, including H.R. 4641 and H.R. 5046; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $290,000 · Firm income: —
Matched citations: S. 524
Medicaid Generic Drug Price Fairness Act of 2014
2016 · first_quarter · Firm: ENDO INTERNATIONAL
Issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; issues relating to FDA approvals of new drugs and generic drugs; issues related to the FDA; issues related to opioids; issues relating to Medicare Part D rebates; H.R. 6, 21st Century Cures, and Senate companion bill, issues relating to the FDA and NIH; H.R.471, S. 483-Ensuring Patient Access and Effective Drug Enforcement Act of 2015; issues relating to the labeling of generic drugs; issues relating to CDC guidance for prescribing opioids; S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act; issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to removal of FDA unapproved products from the market.
Client expense: $790,000 · Firm income: —
Matched citations: H.R. 5748
Protect Medical Innovation Act of 2015
2016 · first_quarter · Firm: ENDO INTERNATIONAL
Issues relating to incentives for life sciences research; H.R. 160 - Protect Medical Innovation Act of 2015; tax treatment of inverted companies; tax issues in mergers and acquisitions of U.S. firms.
Client expense: $790,000 · Firm income: —
Matched citations: H.R. 160
Source: Senate LDA